Experience the Network of the Future, Today with Juniper Networks
Juniper Networks (NYSE:JNPR), a leader in secure, AI-driven networks, will be attending this year’s Mobile World Congress in Barcelona, Spain, with a focus on its ability to deliver “the network of the future” now. This innovation helps customers to provide exceptional user experiences, streamline operational effectiveness and maximize cost efficiencies.
Juniper believes that the network of the future must be built and operated based on five key principles:
- Open – to enable best-in-class solutions and ecosystems
- Automated – to simplify multivendor networks and guarantee service quality
- Cloudified – to deliver optimal agility and adaptability for resources and scale
- Secure – to provide intelligence-led efficacy end-to-end without compromising throughput
- Sustainable – to enable reduced resource consumption and extended lifecycles
Juniper in the News
NEC Launches Value-Added x-Haul Solution Suite with Open Ecosystem (February 16, 2023)
Juniper Networks Expands Collaboration with IBM to Bring Intelligent Automation to Radio Network Solutions (February 23, 2023)
Juniper Networks and Vodafone Deliver Successful First-of-its-Kind Open RAN RIC Trial on a Commercial Network, Highlighting Third-Party Apps Integration (February 23, 2023)
Tele Columbus Deploys Transformational Cloud Metro Infrastructure with Juniper Networks & NEC (February 27, 2023)
Juniper Demos at MWC
Four demos will be available on Juniper’s booth, covering specific solution and use case areas that enable service providers to design, build and operate (and each including inherent, threat-aware security capabilities), comprising:
- Cloud-Delivered Mobile Transport Automation
- Data Center Fabric Management and Telco Cloud
- Open RAN Service Management & Orchestration and RIC
- AI-Driven Enterprise Managed Services
Juniper’s innovative solutions will also be featured in joint demos on numerous partner booths:
Aira / AWS (Juniper
RIC
/rApp) – AWS booth, (Upper Walkway, South Entrance)
AMD (Juniper Connected Security) – (Hall 2 stand 2M61)
IBM (Juniper
RIC
) – (Hall 2 stand 2H20)
Microsoft (Juniper Connected Security) – (Hall 3 stand 3H30)
Wind River (
Juniper Cloud-Native Router
) – (Hall 2 stand 2F25)
Global Mobile Award Nominations
Juniper’s Cloud Metro solution has been shortlisted in the Cloud category of this year’s GLOMO Awards. This category-creating solution applies cloud principles to metro networks, enabling sustainable business growth with future-proof systems, architecture and AI-enabled automation as a service.
Juniper RAN Intelligent Controller (RIC) has also been shortlisted as a key element within partner Rakuten Symphony’s Symworld™ Platform submission in the Best Network Software Breakthrough category.
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005356/en/
Contact information
Media Relations:
Penny Still
Juniper Networks
+44 (0) 1372 385 692
pstill@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom